Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2025-12-15 00:00:00 ET · period of report 2025-12-11 · accession 0001635075-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-15 | 2025-12-11+ | ROIV | Ramaswamy Vivek | 10% | M - OptEx | $12.68 | +7.37M | 34.49M | +27% | +$93.51M |
| DM | 2025-12-15 | 2025-12-11+ | ROIV | Ramaswamy Vivek | 10% | S - Sale+OE | $21.89 | -3.10M | 36.35M | -8% | -$67.94M |
| DM | 2025-12-15 | 2025-12-11+ | ROIV | Ramaswamy Vivek | 10% | J - Other | $21.89 | -4.27M | 33.65M | -11% | -$93.49M |
| DM | 2025-12-15 | 2025-12-11+ | ROIV | Ramaswamy Vivek | 10% | M - OptEx | $0.00 | -7.37M | 22.98M | -24% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2025-12-11 | M | A | 1,869,691 | $12.68 | 35,523,447 | D | — | — | |
| 2 | Common | Common Shares | 2025-12-11 | S | D | 774,142 | $21.64 | 34,749,305 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.35 to $22.05, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. |
| 3 | Common | Common Shares | 2025-12-11 | J | D | 1,095,550 | $21.64 | 33,653,755 | D | — | — | (F2) Represents the "net settlement" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options. (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.35 to $22.05, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. |
| 4 | Common | Common Shares | 2025-12-12 | M | A | 4,672,724 | $12.68 | 38,326,479 | D | — | — | |
| 5 | Common | Common Shares | 2025-12-15 | J | D | 478,708 | $22.05 | 33,653,755 | D | — | — | (F2) Represents the "net settlement" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.88 to $22.49, inclusive. |
| 6 | Common | Common Shares | 2025-12-12 | J | D | 2,696,866 | $21.96 | 33,653,755 | D | — | — | (F2) Represents the "net settlement" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.13, inclusive. |
| 7 | Common | Common Shares | 2025-12-15 | M | A | 832,453 | $12.68 | 34,486,208 | D | — | — | |
| 8 | Common | Common Shares | 2025-12-15 | S | D | 353,745 | $22.05 | 34,132,463 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.88 to $22.49, inclusive. |
| 9 | Common | Common Shares | 2025-12-12 | S | D | 1,975,858 | $21.96 | 36,350,621 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.13, inclusive. |
| 10 | Derivative | Stock Option (Right to Buy) | 2025-12-11 | M | D | 1,869,691 | $0.00 | 27,655,404 | D | $12.68 · — to 2026-03-31 | 1,869,691 Common Stock | (F7) All options exercised by the reporting person would have expired in March 2026 if not exercised. (F6) Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). |
| 11 | Derivative | Stock Option (Right to Buy) | 2025-12-15 | M | D | 832,453 | $0.00 | 22,150,227 | D | $12.68 · — to 2026-03-31 | 832,453 Common Stock | (F7) All options exercised by the reporting person would have expired in March 2026 if not exercised. (F6) Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). |
| 12 | Derivative | Stock Option (Right to Buy) | 2025-12-12 | M | D | 4,672,724 | $0.00 | 22,982,680 | D | $12.68 · — to 2026-03-31 | 4,672,724 Common Stock | (F7) All options exercised by the reporting person would have expired in March 2026 if not exercised. (F6) Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). |